Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tazorac

PreclinicalSmall molecule

FFougera Pharmaceuticals Inc.

Tazorac is one of 11 small molecule programs targeting Tolerance. It is currently in Preclinical.

2

Indications

10

Total Trials

0

Active Trials

10

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToleranceCompleted

Actinic KeratosesCompleted

TolerancePreclinical

Completed

Actinic KeratosesPreclinical

Completed

Competition

Competitive Landscape

12 competitors in Tolerance

#DrugCompanyPhaseTrials

Rituxan

Fludara

Cytoxan

BBaxter Healthcare Corporation

Avigan

AAppili Therapeutics Inc.

Siplizumab

UUniversity of Alabama at Birmingham

Experimental

Levo-Dromoran

VValeant Pharmaceuticals

Tazorac

FFougera Pharmaceuticals Inc.

Oxytocin Treatment

UUniversity of Electronic Science and Technology of China

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis3 trials

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

Completed·BBausch Health Americas, Inc.·Phase 1·NCT03058744·94 enrolled

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Completed·BBausch Health Americas, Inc.·Phase 2·NCT02785159·152 enrolled

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Completed·FFougera Pharmaceuticals Inc.·Phase 3·NCT02886702·855 enrolled

Acne Vulgaris2 trials

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Completed·FFougera Pharmaceuticals Inc.·Phase 3·NCT02886715·1,110 enrolled

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Completed· Sun Pharmaceutical Industries, Inc. logo

Sun Pharmaceutical Industries, Inc.·Phase 1·NCT02411955·1,077 enrolled

Tolerance1 trial

The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance

Completed·UUniversity of Michigan·N/A·NCT00440024·40 enrolled

Actinic Keratoses1 trial

Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses

Completed·SStewart, Roger H., M.D., P.A.·N/A·NCT01053000·10 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Completed·BBausch Health Americas, Inc.·Phase 2·NCT02938494·210 enrolled

2 more indications

Absorption1 trial

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Completed·BBausch Health Americas, Inc.·Phase 1·NCT02849873·48 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

Completed·—·Phase 4·NCT00648986·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Tazorac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tazorac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tazorac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fougera Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFougera Pharmaceuticals Inc.

Related News